{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:08:40Z","timestamp":1740460120873,"version":"3.37.3"},"reference-count":40,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shimizu Foundation","award":["Immunology and Neuroscience Grant"],"award-info":[{"award-number":["Immunology and Neuroscience Grant"]}]},{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["[Grants-in-Aid for scientific research No. 16 K09"],"award-info":[{"award-number":["[Grants-in-Aid for scientific research No. 16 K09"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Most exacerbations of chronic obstructive pulmonary disease (COPD) are triggered by respiratory tract infections. Adaptive immunity<jats:italic>via<\/jats:italic>antibody production is important in preventing infections. Impaired antibody production is reported to be associated with an increased risk of exacerbations of COPD. In the present study, we elucidated whether reduced free light chains (FLCs), which are excessive amounts of light chains produced during antibody synthesis and can be used to estimate systemic antibody production, may be a promising biomarker to predict the risk of exacerbations of COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We enrolled stable male patients with COPD and prospectively observed them for 2\u2005years. At baseline, serum combined FLC (cFLC; sum of kappa and lambda values) and pulmonary function were evaluated. Exacerbation was defined as a worsening of symptoms requiring treatments with antibiotics, corticosteroids or both.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>63 patients with stable COPD were enrolled (72.8\u00b18.1\u2005years, GOLD A\/B\/C\/D=24\/28\/6\/5), and 51 patients completed the 2-year follow-up. Serum cFLC was 31.1\u2005mg\u00b7L<jats:sup>\u22121<\/jats:sup>on average and ranged widely (1.4 to 89.9\u2005mg\u00b7L<jats:sup>\u22121<\/jats:sup>). The patients with low cFLC (below the mean\u2212<jats:sc>sd<\/jats:sc>, n=6) experienced a significantly shorter time to the first exacerbation of COPD (p&lt;0.0001 by the log-rank test). A multivariate Cox proportional hazard model, including the COPD assessment test score, % predicted forced expiratory volume in 1 s (FEV<jats:sub>1<\/jats:sub>% pred), and number of previous exacerbations demonstrated that low cFLC and low FEV<jats:sub>1<\/jats:sub>% pred were independently and significantly correlated with the risk for exacerbations of COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Low cFLC may be a B-cell-associated novel biomarker associated with risk of COPD exacerbation.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00288-2019","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:40:24Z","timestamp":1603280424000},"page":"00288-2019","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Low serum free light chain is associated with risk of COPD exacerbation"],"prefix":"10.1183","volume":"6","author":[{"given":"Kazuya","family":"Tanimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-1090","authenticated-orcid":false,"given":"Susumu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyasu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-0212","authenticated-orcid":false,"given":"Naoya","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Uemasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Hamakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyohiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2020,7,5]]},"reference":[{"key":"2024101707532912000_6.2.00288-2019.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. The Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.com Date last accessed: April 22, 2019."},{"key":"2024101707532912000_6.2.00288-2019.2","first-page":"245","article-title":"Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes","volume":"4","author":"Anzueto","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101707532912000_6.2.00288-2019.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201009-1535OC"},{"key":"2024101707532912000_6.2.00288-2019.4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","article-title":"Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease","volume":"198","author":"Rothnie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101707532912000_6.2.00288-2019.5","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-181"},{"key":"2024101707532912000_6.2.00288-2019.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2024101707532912000_6.2.00288-2019.7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.009","article-title":"Defining the \u201cfrequent exacerbator\u201d phenotype in COPD: a hypothesis-free approach","volume":"153","author":"Le Rouzic","year":"2018","journal-title":"Chest"},{"key":"2024101707532912000_6.2.00288-2019.8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.092858"},{"key":"2024101707532912000_6.2.00288-2019.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.5732"},{"key":"2024101707532912000_6.2.00288-2019.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032158"},{"key":"2024101707532912000_6.2.00288-2019.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01245-2017"},{"key":"2024101707532912000_6.2.00288-2019.12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1165\/rcmb.2017-0373OC","article-title":"Systemic markers of adaptive and innate immunity are associated with chronic obstructive pulmonary disease severity and spirometric disease progression","volume":"58","author":"Halper-Stromberg","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024101707532912000_6.2.00288-2019.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00011211"},{"key":"2024101707532912000_6.2.00288-2019.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1311OC"},{"key":"2024101707532912000_6.2.00288-2019.15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2466-12-37","article-title":"Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation","volume":"12","author":"Yerkovich","year":"2012","journal-title":"BMC Pulm Med"},{"key":"2024101707532912000_6.2.00288-2019.16","doi-asserted-by":"crossref","first-page":"e0194924","DOI":"10.1371\/journal.pone.0194924","article-title":"Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS","volume":"13","author":"Putcha","year":"2018","journal-title":"PLoS One"},{"key":"2024101707532912000_6.2.00288-2019.17","doi-asserted-by":"crossref","first-page":"e0167250","DOI":"10.1371\/journal.pone.0167250","article-title":"Relationships between mucosal antibodies, non-typeable Haemophilus influenzae (NTHi) infection and airway inflammation in COPD","volume":"11","author":"Staples","year":"2016","journal-title":"PLoS ONE"},{"key":"2024101707532912000_6.2.00288-2019.18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","article-title":"Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity","volume":"13","author":"Lanteri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2024101707532912000_6.2.00288-2019.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025392"},{"key":"2024101707532912000_6.2.00288-2019.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200506-859OC"},{"key":"2024101707532912000_6.2.00288-2019.21","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(86)90191-7"},{"key":"2024101707532912000_6.2.00288-2019.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008378"},{"key":"2024101707532912000_6.2.00288-2019.23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.resinv.2014.03.003","article-title":"Clinical Pulmonary Functions Committee of the Japanese Respiratory S. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values","volume":"52","author":"Kubota","year":"2014","journal-title":"Respir Investig"},{"key":"2024101707532912000_6.2.00288-2019.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7245.1297"},{"key":"2024101707532912000_6.2.00288-2019.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201509-1869OC"},{"key":"2024101707532912000_6.2.00288-2019.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.010"},{"key":"2024101707532912000_6.2.00288-2019.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01162-2017"},{"key":"2024101707532912000_6.2.00288-2019.28","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/COPD.S129787","article-title":"Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD","volume":"12","author":"Zysman","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101707532912000_6.2.00288-2019.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172437"},{"key":"2024101707532912000_6.2.00288-2019.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0761OC"},{"key":"2024101707532912000_6.2.00288-2019.31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12931-018-0733-z","article-title":"Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD","volume":"19","author":"Filho FS","year":"2018","journal-title":"Respir Res"},{"key":"2024101707532912000_6.2.00288-2019.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.03.007"},{"key":"2024101707532912000_6.2.00288-2019.33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2003.01191.x"},{"key":"2024101707532912000_6.2.00288-2019.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.05.001"},{"key":"2024101707532912000_6.2.00288-2019.35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037483"},{"key":"2024101707532912000_6.2.00288-2019.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211855"},{"key":"2024101707532912000_6.2.00288-2019.37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12931-016-0348-1","article-title":"Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD","volume":"17","author":"Hampson","year":"2016","journal-title":"Respir Res"},{"key":"2024101707532912000_6.2.00288-2019.38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijcard.2015.03.105","article-title":"Free light chains in patients with acute coronary syndromes: relationships to inflammation and renal function","volume":"185","author":"Shantsila","year":"2015","journal-title":"Int J Cardiol"},{"key":"2024101707532912000_6.2.00288-2019.39","doi-asserted-by":"crossref","first-page":"e40570","DOI":"10.1371\/journal.pone.0040570","article-title":"Relationship between periodontitis-related antibody and frequent exacerbations in chronic obstructive pulmonary disease","volume":"7","author":"Takahashi","year":"2012","journal-title":"PLoS ONE"},{"key":"2024101707532912000_6.2.00288-2019.40","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-10-108"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00288-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:04:36Z","timestamp":1740373476000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00288-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,5]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1183\/23120541.00288-2019"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00288-2019","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}